State-Level Marketing Restrictions Increasingly Target Device Industry
This article was originally published in The Gray Sheet
Executive Summary
As more states try to exert control over marketing by pharmaceutical manufacturers, it appears increasingly likely that device companies will become swept up in the tide
You may also be interested in...
Industry Calls For Stronger Coalitions To Advocate At The State Level
Budget shortfalls in state governments throughout the country increase the importance of strong industry coalitions at that level to lobby on behalf of medical technology, industry representatives say
Flourishing In the Sunshine: Disclosure as a new Commercial Advantage
Orthopedic device manufacturers are out ahead of the drug industry in adapting to new payment disclosure laws. One company, Stryker, has embraced the requirement wholeheartedly and may have found a way to make the listing a benefit to doctors and patients.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.